ArticleBMC infectious diseases2020
Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study.
Article in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- [Drug resistance characteristics of pulmonary tuberculosis and factors associated with rifampicin resistance in Changsha from 2018 to 2025].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Article
- Prevalence of drug resistant tuberculosis and its associated factors among tuberculosis patients at wolkite health center in central Ethiopia.Scientific reports · 2026Article
- Drug Resistance Patterns, Temporal Trends, and Risk Factors Among Elderly Tuberculosis Patients in Anhui, China: A Retrospective Study (2020-2024).Infection and drug resistance · 2026Article
- Effect of Isoniazid Resistance on Treatment Outcome Among People With Pulmonary Tuberculosis in Korea.Journal of Korean medical science · 2025Article
- Chest CT findings in drug-resistant pulmonary tuberculosis: a comparative analysis of elderly and non-elderly patients.BMC infectious diseases · 2025Article
- Trends in Drug Resistance and Epidemiological Patterns of Tuberculosis in Elderly Patients in Wenzhou, China (2014-2023).Infection and drug resistance · 2025Article
- Clinical Profiles of Multidrug-Resistant and Rifampicin-Monoresistant Tuberculosis in Korea, 2018-2021: A Nationwide Cross-Sectional Study.Tuberculosis and respiratory diseases · 2025Article
- Drug-resistant tuberculosis: a persistent global health concern.Nature reviews. Microbiology · 2024Review
- Trends of Mycobacterium tuberculosis and Rifampicin resistance in Northwest Ethiopia: Xpert® MTB/RIF assay results from 2015 to 2021.BMC infectious diseases · 2024Article
- Determinants of drug-resistant tuberculosis in Hunan province, China: a case-control study.BMC infectious diseases · 2024Article
- Drug-resistant Mycobacterium tuberculosis among Nepalese patients at a tuberculosis referral center.PloS one · 2024Article
- Delphi Survey on the Current and Future Korean Guidelines for Isoniazid-Monoresistant Tuberculosis.Infection and drug resistance · 2023Article
- Comparison of different regimens with or without fluoroquinolone in isoniazid-resistant tuberculosis: A multicenter cohort study.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe emergence of drug-resistant tuberculosis (DR-TB) is a major healthcare concern worldwide. Here, we analyzed age-related trends in DR-TB rates in South Korea.
methodsDrug susceptibility test results were collected from patients with culture-confirmed TB between 2015 and 2018 from eight university-affiliated hospitals. Patients were divided into three subgroups: younger (15-34 years), middle (35-59 years), and older (≥60 years) to compare drug-resistance patterns. To evaluate trends in age-stratified drug-resistance, chi-square test for linear trends was performed.
resultsAmong enrolled native patients aged ≥15 years, 4.1% (179/4417), 1.2% (53/4417) and 7.2% (316/4417) were multidrug-resistant TB (MDR-TB), rifampicin-mono-resistant TB (RR-TB), and isoniazid-mono-resistant TB (Hr-TB), respectively. Proportions of Hr-TB cases were 5.4% (40/734), 7.2% (114/1593), and 7.8% (162/2090) in the younger, middle and older age groups, respectively. MDR/RR-TB case rates decreased significantly with age from 8.6% (63/734) in younger age group to 3.3% (68/2090) in older age group. Fluoroquinolone resistance was highest among second-line drugs, and there were no differences in resistance to fluoroquinolones and second-line injectable drugs among the three age groups.
conclusionsThe number of MDR/RR-TB cases was highest in young patients. Effective public health interventions should include increased focus on rifampicin resistance in young patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.